AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16644856 — intervention group
Group type: EXPERIMENTAL
Intervention: MVD present
Number of subjects: 395
Study 16644856 — intervention group
Group type: COMPARATOR
Intervention: Non-MVD
Number of subjects: 395
Study 15257968 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vests
Number of subjects: 514
Study 11565972 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing tasks at 3 m and 9 m high balconies on firm or deformable surfaces with close visual references included
Number of subjects: 24
Study 11565972 — intervention group
Group type: COMPARATOR
Intervention: Standing tasks at ground level
Number of subjects: 24
Study 11565972 — intervention group
Group type: EXPERIMENTAL
Intervention: Deformable surfaces without close visual references
Number of subjects: 24
Study 11565972 — intervention group
Group type: EXPERIMENTAL
Intervention: Close visual references included
Number of subjects: 24
Study 9316325 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative analgesia of intravenous (i.v.) meperidine HCl (Demerol)
Number of subjects: 40
Study 9316325 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive analgesia using epidural infusion of local anesthetics plus ketamine and morphine during surgery, and intermittent epidural morphine infusion for postoperative pain control when necessary, along with i.v. Demerol as in Group A
Number of subjects: 40
Study 9316325 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 40
Study 9316325 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 40
Study 8466013 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 78
Study 8466013 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 78
Study 3567016 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 20 mg
Number of subjects: 12
Study 3567016 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 40 mg
Number of subjects: 12
Study 3567016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31571349 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IVIg (2g/kg loading dose, 1g/kg maintenance every 3 weeks) and IVMP (1g every 3 weeks for 18 weeks); cumulative steroid dose 7g
Number of subjects: 20
Study 30514858 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrophic gastritis (PGI < 30 μg/L or PGI: PGII < 3.0)
Number of subjects: 1591
Study 30514858 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA antibody positive
Number of subjects: 1591
Study 30514858 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrophic gastritis
Number of subjects: 1591
Study 26505825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med diet)
Number of subjects: 20
Study 26505825 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet (LFHCC diet)
Number of subjects: 20
Study 25248446 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulmonary rehabilitation training (air-stacking exercise by ambu-bagging and functional electrical stimulation on phrenic nerve and abdominal muscle)
Number of subjects: 22
Study 25248446 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active pulmonary rehabilitation)
Number of subjects: 22
Study 22681259 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.1% hydrogel patch
Number of subjects: 61
Study 22681259 — intervention group
Group type: COMPARATOR
Intervention: Control hydrogel patch without capsaicin
Number of subjects: 61
Study 20493191 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fat (HF) cream cheese
Number of subjects: 10
Study 20493191 — intervention group
Group type: COMPARATOR
Intervention: Lower fat (LF) cream cheese
Number of subjects: 10
Study 17568412 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/kg i.v. glucose
Number of subjects: 24
Study 17568412 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 24
Study 15743346 — intervention group
Group type: EXPERIMENTAL
Intervention: On medications for heartburn
Number of subjects: 158
Study 15743346 — intervention group
Group type: COMPARATOR
Intervention: Off medications for 1 week while symptomatic
Number of subjects: 158
Study 15743346 — intervention group
Group type: EXPERIMENTAL
Intervention: On and off antireflux medications
Number of subjects: 158
Study 15743346 — intervention group
Group type: COMPARATOR
Intervention: Off medications for patients with comorbid conditions
Number of subjects: 158
Study 12036207 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal water from Cserkeszölö (active treatment)
Number of subjects: 58
Study 12036207 — intervention group
Group type: COMPARATOR
Intervention: Tap water (placebo treatment)
Number of subjects: 58
Study 9951980 — intervention group
Group type: EXPERIMENTAL
Intervention: High titer measles vaccine
Number of subjects: 224
Study 9951980 — intervention group
Group type: EXPERIMENTAL
Intervention: High titer measles vaccine with rash
Number of subjects: 224
Study 9951980 — intervention group
Group type: EXPERIMENTAL
Intervention: High titer measles vaccine without rash
Number of subjects: 224
Study 9951980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 1824203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (L)
Number of subjects: 31
Study 1824203 — intervention group
Group type: COMPARATOR
Intervention: Probucol (P)
Number of subjects: 31
Study 1824203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 31
Study 7017966 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg
Number of subjects: 0
Study 7017966 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 0
Study 30485658 — intervention group
Group type: EXPERIMENTAL
Intervention: Orobanche rapum extract
Number of subjects: 0
Study 29081160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg loading dose and 10 mg·kg(‐1)·h(‐1) infusion dose)
Number of subjects: 211
Study 29081160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 211
Study 25143294 — intervention group
Group type: COMPARATOR
Intervention: VLNC + PLA (very low nicotine content cigarettes with placebo patches)
Number of subjects: 57
Study 25143294 — intervention group
Group type: EXPERIMENTAL
Intervention: VLNC + NIC (very low nicotine content cigarettes with nicotine patches totaling 42mg)
Number of subjects: 57
Study 25143294 — intervention group
Group type: COMPARATOR
Intervention: Usual-brand cigarettes
Number of subjects: 57
Study 23557872 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at CV12 (abdomen)
Number of subjects: 0
Study 23557872 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at BL32 (sacral)
Number of subjects: 0
Study 23557872 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at PC6 (forearm), BL20 (back), ST36 (lower leg)
Number of subjects: 0
Study 21324825 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine 3 times daily
Number of subjects: 343
Study 21324825 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine 2 times daily
Number of subjects: 343
Study 21324825 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine 1 time daily
Number of subjects: 343
Study 21324825 — intervention group
Group type: COMPARATOR
Intervention: Insulin glulisine 1 or 2 times daily
Number of subjects: 343
Study 19147693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial 12 weeks) followed by open active treatment as clinically indicated
Number of subjects: 439
Study 19147693 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatments (fluoxetine, CBT, combination treatment)
Number of subjects: 439
Study 17723125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg
Number of subjects: 1309
Study 17723125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1309
Study 14998381 — intervention group
Group type: EXPERIMENTAL
Intervention: Eformoterol Turbohaler 9 microg b.i.d
Number of subjects: 156
Study 14998381 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol Accuhaler 50 microg b.i.d
Number of subjects: 156
Study 11916358 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem treatment
Number of subjects: 72
Study 11916358 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 72
Study 9496329 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU of s.c. recombinant human LH
Number of subjects: 12
Study 9496329 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU of s.c. recombinant human FSH
Number of subjects: 12
Study 9496329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of recombinant human LH and FSH
Number of subjects: 12
Study 8110566 — intervention group
Group type: COMPARATOR
Intervention: Group B10 (10 micrograms kg‐1 bolus dose)
Number of subjects: 40
Study 8110566 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B20 (20 micrograms kg‐1 bolus dose)
Number of subjects: 40
Study 3349887 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (6 g daily)
Number of subjects: 8
Study 3349887 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (7.2 g daily)
Number of subjects: 8
Study 3349887 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 29985228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates method training (60 minutes, 3 times per week for 12 weeks)
Number of subjects: 22
Study 29985228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates method training
Number of subjects: 22
Study 31647614 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) with albuminuria
Number of subjects: 535
Study 31647614 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) without albuminuria
Number of subjects: 535
Study 31647614 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus with albuminuria
Number of subjects: 535
Study 31647614 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) without albuminuria developing albuminuria
Number of subjects: 535
Study 28993394 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape‐Up following cancer treatment programme (12 hours over 8 weeks)
Number of subjects: 60
Study 28993394 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 60
Study 25256304 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners' use of argumentation to support treatment advice
Number of subjects: 0
Study 25256304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 22809774 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal 4% lidocaine
Number of subjects: 0
Study 22809774 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 19898884 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (breathing and aerobic exercises) for 1.5 h, 3 days weekly for 12 weeks
Number of subjects: 20
Study 19898884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 18924387 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based psychosocial interventions
Number of subjects: 0
Study 18924387 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional and technology-enhanced interventions
Number of subjects: 0
Study 18924387 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative therapies
Number of subjects: 0
Study 16611272 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin 800 mg b.d.
Number of subjects: 83
Study 16611272 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin 800 mg o.d. + placebo
Number of subjects: 83
Study 16611272 — intervention group
Group type: COMPARATOR
Intervention: placebo b.d.
Number of subjects: 83
Study 14708688 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg daily lamivudine therapy
Number of subjects: 0
Study 11056097 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg) daily
Number of subjects: 2763
Study 11056097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study 9014880 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact sheets and subsequent discussion
Number of subjects: 33
Study 9014880 — intervention group
Group type: COMPARATOR
Intervention: Fact sheets alone
Number of subjects: 33
Study 9014880 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact sheets
Number of subjects: 33
Study 1507822 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PA) as a treatment
Number of subjects: 92
Study 1507822 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis with elimination of one volume of circulating plasma (VCP)
Number of subjects: 92
Study 1507822 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis with elimination of 1/2 VCP
Number of subjects: 92
Study 1507822 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis with elimination of 1/4 VCP
Number of subjects: 92
Study 1507822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 92
Study 6742082 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% eyedrops (used twice a day)
Number of subjects: 9
Study 6742082 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg (three times a day, given orally)
Number of subjects: 9
Study 6742082 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% eyedrops with Indomethacin
Number of subjects: 9
Study 31135106 — intervention group
Group type: EXPERIMENTAL
Intervention: Incised groups (skin incised wound model)
Number of subjects: 45
Study 31135106 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninjured skin tissue)
Number of subjects: 45
Study 27935183 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 500
Study 27935183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 25677354 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram plus methylphenidate
Number of subjects: 143
Study 25677354 — intervention group
Group type: COMPARATOR
Intervention: Citalopram plus placebo
Number of subjects: 143
Study 25677354 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate plus placebo
Number of subjects: 143
Study 24307559 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable saccade task (PRED)
Number of subjects: 45
Study 24307559 — intervention group
Group type: EXPERIMENTAL
Intervention: Position predictable saccade task (pPRED)
Number of subjects: 45
Study 24307559 — intervention group
Group type: EXPERIMENTAL
Intervention: Time predictable saccade task (tPRED)
Number of subjects: 45
Study 24307559 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosaccade task (SAC)
Number of subjects: 45
Study 22930049 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 87
Study 22930049 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education intervention)
Number of subjects: 87
Study 20019606 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (n-3 FA), specifically docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)
Number of subjects: 0
Study 20019606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish consumption as part of a balanced diet
Number of subjects: 0
Study 20019606 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA as a treatment option
Number of subjects: 0
Study 17181846 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg administered pre- and postoperatively
Number of subjects: 79
Study 17181846 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered pre- and postoperatively
Number of subjects: 79
Study 15224032 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-level N2 disease
Number of subjects: 172
Study 15224032 — intervention group
Group type: COMPARATOR
Intervention: N1 disease
Number of subjects: 172
Study 15224032 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-level N2 metastases without concomitant N1 disease (skip metastases)
Number of subjects: 172
Study 15224032 — intervention group
Group type: COMPARATOR
Intervention: Both N1 and N2 metastases
Number of subjects: 172
Study 15224032 — intervention group
Group type: COMPARATOR
Intervention: Left upper lobe tumors with N1 disease
Number of subjects: 172
Study 15224032 — intervention group
Group type: EXPERIMENTAL
Intervention: Left upper lobe tumors with single-level N2 disease
Number of subjects: 172
Study 11772245 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 0
Study 11772245 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management strategies
Number of subjects: 0
Study 11772245 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification (addition of dietary fibre)
Number of subjects: 0
Study 11772245 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacological agents
Number of subjects: 0
Study 11772245 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative therapies (homeopathy, acupuncture, special diets, herbal medication, psychological treatments, hypnotherapy)
Number of subjects: 0
Study 9498441 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma HIV RNA levels
Number of subjects: 0
Study 9498441 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 10-fold lower HIV RNA concentration at baseline
Number of subjects: 0
Study 9498441 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 10-fold decrease in HIV RNA between baseline and week 8
Number of subjects: 0
Study 9498441 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analyses of baseline values or changes in infectious HIV titer or ICD p24 antigen concentrations
Number of subjects: 0
Study 9498441 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma HIV-1 RNA
Number of subjects: 0
Study 7974334 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight adjusted dose of Fragmin (100 IU/kg) subcutaneously twice a day for 10 days (group A)
Number of subjects: 122
Study 7974334 — intervention group
Group type: COMPARATOR
Intervention: Dosage based on anti factor Xa assay to obtain a target concentration of 0.5 to 1 IU/ml (group B)
Number of subjects: 122
Study 7974334 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 122
Study 2690622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg given twice daily
Number of subjects: 0
Study 2690622 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin 764 mg given every six hours
Number of subjects: 0
Study 2690622 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole combination
Number of subjects: 0
Study 2690622 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin
Number of subjects: 0
Study 790112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 0
Study 790112 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 790112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31527572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 50
Study 31527572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31096266 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (48 IU/day)
Number of subjects: 124
Study 28654019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's skim milk fermented with Lactobacillus paracasei CBA L74 (group A)
Number of subjects: 126
Study 28654019 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrins, group B)
Number of subjects: 126
Study 24916134 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (A)
Number of subjects: 84
Study 24916134 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (M)
Number of subjects: 84
Study 24916134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of magnesium sulfate and albuterol (M + A)
Number of subjects: 84
Study 23454551 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT (Cognitive and Behavioural Therapy) for 6 months
Number of subjects: 68
Study 23454551 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 68
Study 21300930 — intervention group
Group type: EXPERIMENTAL
Intervention: AC→T (sequential doxorubicin and cyclophosphamide followed by docetaxel)
Number of subjects: 0
Study 21300930 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (concurrent doxorubicin, cyclophosphamide, and docetaxel)
Number of subjects: 0
Study 21300930 — intervention group
Group type: EXPERIMENTAL
Intervention: AT (doxorubicin and tamoxifen)
Number of subjects: 0
Study 21300930 — intervention group
Group type: EXPERIMENTAL
Intervention: AC→T
Number of subjects: 0
Study 21300930 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study 21300930 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm, time point, age, and tamoxifen use
Number of subjects: 0
Study 19011957 — intervention group
Group type: EXPERIMENTAL
Intervention: Using clinical irrelevance criteria for covariate selection
Number of subjects: 1445
Study 19011957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dividing elimination into renal and non-renal parts
Number of subjects: 1445
Study 19011957 — intervention group
Group type: EXPERIMENTAL
Intervention: First-order (FO) and first-order conditional estimation (FOCE) methods
Number of subjects: 1445
Study 16569562 — intervention group
Group type: EXPERIMENTAL
Intervention: FilterWire EX
Number of subjects: 651
Study 16569562 — intervention group
Group type: COMPARATOR
Intervention: GuardWire
Number of subjects: 651
Study 12913194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight exposure for 12 months
Number of subjects: 258
Study 12913194 — intervention group
Group type: COMPARATOR
Intervention: Sunlight deprivation (control group)
Number of subjects: 258
Study 10859037 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 236
Study 10859037 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 236
Study 9101627 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred, self-directive intervention
Number of subjects: 110
Study 9101627 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 110